Royalty Report: Drugs, Pain, Pharmaceuticals – Collection: 26353


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 10


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 10

Primary Industries

  • Drugs
  • Pain
  • Pharmaceuticals
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26353

License Grant
The Licensor and the Licensee entered in to a worldwide exclusive Agreement for the development and commercialization of Relistor.
License Property
Relistor is for the treatment of opioid induced constipation, specifically designed to block the constipating effects of opioid pain medications in the gastrointestinal tract.
Field of Use
The Licensee will further developing and commercializing Rlistor, including completing clinical development necessary to support regulatory marketing approvals for potential new indications and formulations of the drug, such as oral methylnaltrexone.

IPSCIO Record ID: 3196

License Grant
Licensor hereby grant to Licensee, and Licensee hereby accepts in respect of the Licensed Technology and the Licensors’ interest in the Joint Technology:  (a) the exclusive license, even as to the Licensor and their Affiliates, with the right to grant Sublicenses (i) to Develop the Compound and Products in the Territory for use and Commercialization in the Field in the Territory and (ii) to Commercialize Products in the Field in the Territory; and (b) a non-exclusive license, with the right to grant Sublicenses to Manufacture or have Manufactured in the Territory (i) Products for use or Commercialization by Licensee and its Sublicensees under the license granted and (ii) Compound for incorporation into such Products.

The Licensor granted License of relevant know-how, patent rights and technology,for Relistor® (methylnaltrexone bromide) subcutaneous injection, to the Licensee, a leading gastrointestinal disease specialty company.

License Property
Relistor (methylnaltrexone bromide) subcutaneous injection is a first-in-class therapy for opioid-induced constipation (OIC).

OIC is the constipation that often arises when patients take opioids for pain relief.

IPSCIO Record ID: 26279

License Grant
The Licensor entered into a collaboration Agreement with the Licensee for the exclusive worldwide development and commercialization of Entereg for certain indications. The Licensor is responsible for the development of acute indications, such as postoperative ileus, and the Licensee is responsible for the development of chronic indications, such as opioid bowel dysfunction. In the United States, the Licensee and the Licensor are co-developing Entereg and intend to share profits or losses that result from the sale of the product.
License Property
Entereg is a drug which behaves as a peripherally acting µ-opioid antagonist. With limited ability to cross the blood–brain barrier, many of the undesirable side-effects of the opioid agonists such as constipation are minimized without affecting analgesia or precipitating withdrawal.

Opioid analgesics provide pain relief by stimulating opioid receptors located in the central nervous system. There are, however, opioid receptors throughout the body, including the GI tract. By binding to the receptors in the GI tract, opioid analgesics can slow gut motility and disrupt normal GI function that allows for the passage, absorption and excretion of ingested solid materials. This disruption can cause patients to experience significant discomfort and abdominal pain and may result in their reducing or eliminating their pain medication.
Entereg is a small molecule, mu-opioid receptor antagonist intended to block the adverse side effects of opioid analgesics on the GI tract without affecting analgesia. We are developing Entereg for both acute and chronic conditions.

IPSCIO Record ID: 2796

License Grant
The Licensor's lead product is Relistorâ„¢ (methylnaltrexone bromide). On April 24, 2008, Relistor subcutaneous injection was approved by the U.S. Food and Drug Administration for sale in the United States for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Our collaboration partner, the Licensee, commenced sales of Relistor subcutaneous injection in the U.S. in June 2008.
Field of Use
The rights granted apply in the medical industry.

IPSCIO Record ID: 203524

License Grant
Licensor grants an exclusive, except as to Licensor for internal research purposes only and not for clinical development, license under Know How, the Licensed Patents arid the Process Licensed Patents, to develop, obtain Regulatory Approval for, use, make, have made, import, sell, and offer for sale New Compounds and New Products in the Territory.
License Property
The patents, related foreign equivalents and know-how relate to peripherally selective opioid antagonists.

The New Compound shall mean a chemical entity (including salts and solvates thereof, which shall be considered the same New Compound for purposes of this Agreement) covered by any valid and unexpired claim of Licensed Patents, but shall exclude in all cases the Roberts Agreement Compound.

The New Product means a finished, formulated pharmaceutical product containing a New Compound, together with all improvements and line extensions thereon which may be included in any supplement, modification or addition to the relevant Regulatory Approval to the extent that any such improvements or line extensions contain a New Compound.

Field of Use
The Field of Use means all uses as a Peripherally Selective Opioid Receptor Antagonist, where the term Peripherally Selective Opioid Receptor Antagonist shall mean a chemical entity that has a selectivity ratio of greater than 20 upon parenteral administration as measured by the ED-50 for antagonism of analgesia in the mouse writhing test in morphine-naive mice divided by the ED-50 for precipitation of diarrhea in the morphine-dependent mice test.

Licensee is developing  alvimopan, a peripherally selective mu opioid antagonist for management of postoperative ileus, opioid induced bowel dysfunction and certain other indications.  Alvimopan is in a class of medications called peripherally acting mu-opioid receptor antagonists. It works by protecting the bowel from the constipation effects of opioid (narcotic) medications that are used to treat pain after surgery.

IPSCIO Record ID: 233488

License Grant
The Licensor and Chinese Licensee entered into an exclusive licensing agreement for the development and commercialization of Oliceridine in United States and China.
License Property
Oliceridine is a G protein biased ligand of the µ opioid receptor, for the management of moderate-to-severe acute pain where intravenous, or IV, administration is preferred.
Field of Use
Oliceridine is an opioid drug that is under evaluation in human clinical trials for the intravenous treatment of severe acute pain.

IPSCIO Record ID: 266021

License Grant
The parties entered into an exclusive license agreement  for the commercialization of Symproic® (naldemedine tosylate) (the Product) in the United States including Puerto Rico (the Territory) for opioid-induced constipation in adult patients with chronic non-cancer pain (the Field).
License Property
Symproic® (naldemedine) is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids, in adults with long-lasting (chronic) pain that is not caused by active cancer.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 183240

License Grant
The Licensor announced the signing of exclusive global license and supply agreements with the Licensee for three captisol enabled programs, one of which is Meloxicam
License Property
Captisol is a modified cyclodextrin preparation, designed to optimize the solubility and stability of drugs.

Captisol-enabledâ„¢ Meloxicam is an intravenous (IV) and intramuscular (IM) version of meloxicam specifically formulated to provide an option for hospital patients suffering from acute post-surgery, trauma and cancer pain following use of IV/IM NSAIDs and in place of or delaying use of IV/IM opioids, which put patients at risk for addiction, respiratory depression, sedation and constipation. Mobic (meloxicam) is currently only available in an oral formulation.

Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.  IM/IV CE Meloxicam is for patients with acute pain

Field of Use
This agreement is for the drug industry.

IPSCIO Record ID: 2939

License Grant
An exclusive License Agreement that grants the Licensee an exclusive License to develop and commercialize Opana® and Opana® ER in Canada, Australia and New Zealand.  Regulatory approval must be received prior to any sale of the Licensed products.
License Property
Opana is in a group of drugs called narcotic pain relievers. It is similar to morphine.  Opana is used to treat moderate to severe pain.  Opana ER contains oxymorphone, which is a morphine-like opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.
Field of Use
The rights granted apply to the healthcare industry relating to the drug market.

IPSCIO Record ID: 111868

License Grant
Licensor grants an exclusive, world-wide license to make, have made, use, sell or import Product pursuant to the Intellectual Property Rights or any other Licensor Technical Information. The term of the license shall be either the term of Phase A or, if Licensee elects to proceed with Phase B, the sum of the terms of Phase A and Phase B.

Phase A is for completing studies sufficient to establish the therapeutic index of the Compound and of whether Licensee intends to initiate Phase B.  Phase B is for developing and commercializing the Compound or Product.

License Property
Licensor has acquired from a third party, an exclusive, world-wide license to make, have made, use or sell (+)-[2(S)-[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]-acetic acid and all pharmaceutically acceptable salts and solvates thereof (the Compound), with the right to sublicense.

ADL 8-2698 is a peripherally-acting, gastrointestinal tract-restricted mu opioid receptor antagonist.  ADL 8-2698 is for treatment of narcotic bowel dysfunction.
Narcotic bowel syndrome (NBS) is a subset of opioid bowel dysfunction that is characterized by chronic or frequently recurring abdominal pain that worsens with continued or escalating dosages of narcotics.  As a result of the undesired action of opioids on the gastrointestinal (GI) tract, patients receiving opioid medication for chronic pain often experience opioid-induced bowel dysfunction (OBD), the most common and debilitating symptom of which is constipation.

Field of Use
Licensee is engaged in the development and marketing of therapeutic products utilizing opiate receptor-mediated pathways.

Licensee are developing orally-administered ADL 8-2698 to block the adverse gastrointestinal side effects of narcotics without blocking the beneficial analgesic effects. These gastrointestinal side effects include narcotic bowel dysfunction, ileus, which is delayed recovery of bowel function after surgery, and nausea.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.